OPTIMIZE
A Phase II Study of Reduced Dose Post Transplantation Cyclophosphamide as GvHD Prophylaxis in Adult Patients With Hematologic Malignancies Receiving HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 2
- Enrollment
- 190 patients (estimated)
- Sponsors
- Center for International Blood and Marrow Transplant Research
- Collaborators
- National Marrow Donor Program (NMDP)
- Tags
- Allogeneic Stem Cell Transplant
- Trial Type
- Treatment
- Last Update
- 1 month ago
- SparkCures ID
- 1747
- NCT Identifier
- NCT06001385
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.